Cargando...
Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis
AIMS/INTRODUCTION: To assess the effect of dulaglutide (DU) 1.5/0.75 mg in comparison with glimepiride (GLIM) or insulin glargine (GLAR) on the composite end‐point in Chinese type 2 diabetes patients. MATERIALS AND METHODS: Post‐hoc analyses of two randomized phase III trials (NCT01644500 and NCT016...
Gardado en:
| Publicado en: | J Diabetes Investig |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7232276/ https://ncbi.nlm.nih.gov/pubmed/31758850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13187 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|